Uploaded July 2026 | Updated September 2026, 3 weeks ago
An FDA advisory panel voted to support broader access to compounded wellness peptides, including BPC-157 and TB-500, despite concerns over limited human evidence and uncertain safety. While the recommendation is not binding, it signals growing pressure to balance consumer demand with stronger clinical evidence and regulatory oversight.
Full Episode on YouTube, Spotify and Apple Podcast. Link in the comment.
#LongevityTechnologyUnlocked #LongevityPodcast #Peptides #BPC157 #ClinicalEvidence #Regulation
An FDA advisory panel voted to support broader access to compounded wellness peptides, including BPC-157 and TB-500, despite concerns over limited human evidence and uncertain safety. While the recommendation is not binding, it signals growing pressure to balance consumer demand with stronger clinical evidence and regulatory oversight.
Full Episode on YouTube, Spotify and Apple Podcast. Link in the comment.
#LongevityTechnologyUnlocked #LongevityPodcast #Peptides #BPC157 #ClinicalEvidence #Regulation
